QUARTERLY FINANCIAL RESULTS AND MARKET FOR THE COMPANY'S STOCK (UNAUDITED) (Tables)

12 Months Ended

Dec. 31, 2020

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Results and Market for the Company's Stock


Years Ended December 31,	First Quarter		Second Quarter		Third Quarter		Fourth Quarter		Total Year
	(in millions, except per share data)
2020
Net sales	$	1,128.7	$	925.0	$	1,140.9	$	1,191.7	$	4,386.3
Gross profit	863.6		686.8		859.9		895.4		3,305.7
Net income (loss) (a)	310.6		(121.9)		325.2		309.5		823.4
Earnings (loss) per common share (a):
Basic	0.50		(0.20)		0.52		0.50		1.32
Diluted	0.49		(0.20)		0.52		0.49		1.30
Market price:
High	$	81.90	$	78.43	$	87.79	$	92.08	$	92.08
Low	51.51		56.44		66.87		70.92		51.51
2019
Net sales	$	993.0	$	1,086.9	$	1,094.0	$	1,174.1	$	4,348.0
Gross profit	761.2		782.9		801.6		887.9		3,233.6
Net income (b)	249.7		242.3		274.7		280.2		1,046.9
Earnings per common share (b):
Basic	0.40		0.39		0.44		0.45		1.68
Diluted	0.39		0.38		0.43		0.44		1.64
Market price:
High	$	65.95	$	65.00	$	76.06	$	82.55	$	82.55
Low	46.95		55.23		61.00		71.08		46.95

_______________________________________________________________________________

(a) The second quarter of 2020 includes a $367.9 million charge related to a litigation settlement.

(b) The first quarter of 2019 includes a $24.0 million charge related to the acquisition of early-stage transcatheter intellectual property and associated clinical and regulatory experience. The second and third quarters of 2019 include a $46.2 million and $26.9 million charge, respectively, related to the write off of inventory. The fourth quarter of 2019 includes a $40.6 million charge related to the impairment of certain in-process research and development assets.